6-{3-[(Pyridin-2-yl)disulfanyl]propanamido}hexanoic acid | 79741-17-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 6-{3-[(Pyridin-2-yl)disulfanyl]propanamido}hexanoic acid
• 英文别名: 6-[3-(pyridin-2-yldisulfanyl)propanoylamino]hexanoic acid
• CAS: 79741-17-6
• 化学式: C₁₄H₂₀N₂O₃S₂
• 分子量: 328.5
• InChiKey: KPFOKUHANTWLRQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  21
• 可旋转键数：
  11
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  130
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  3-(2-吡啶基二硫基)丙酸N-羟基琥珀酰亚胺酯 、 6-氨基己酸 、 三乙胺 生成 6-{3-[(Pyridin-2-yl)disulfanyl]propanamido}hexanoic acid
  参考文献：
  名称：

  VOISIN, G. A.;JANSEN, F. K.;GROS, P.

  摘要：

  DOI：

文献信息

• [EN] DERIVATIVES OF AMANITA TOXINS AND THEIR CONJUGATION TO A CELL BINDING MOLECULE<br/>[FR] DÉRIVÉS DE TOXINES D'AMANITES ET LEUR CONJUGAISON À UNE MOLÉCULE DE LIAISON CELLULAIRE
  申请人：HANGZHOU DAC BIOTECH CO LTD

  公开号：WO2017046658A1

  公开（公告）日：2017-03-23

  Derivatives of Amernita toxins of Formula (I), wherein, formula (a) R 1, R 2, R 3, R 4, R 5, R 6, R 7, R 8, R 9, R 10, X, L, m, n and Q are defined herein. The preparation of the derivatives. The therapeutic use of the derivatives in the targeted treatment of cancers, autoimmune disorders, and infectious diseases.

  Amernita毒素的衍生物的化学式（I），其中，化学式（a）中的R 1、R 2、R 3、R 4、R 5、R 6、R 7、R 8、R 9、R 10、X、L、m、n和Q在此处被定义。这些衍生物的制备。这些衍生物在靶向治疗癌症、自身免疫性疾病和传染病中的治疗用途。
• Conjugation product
  申请人：Molmed SpA

  公开号：EP2364995A1

  公开（公告）日：2011-09-14

  A peptide which selectively inhibits αvβ3 integrin which comprises the deamidation product of a peptide comprising the NGR motif.

  一种选择性抑制 αvβ3 整合素的多肽，它包括由 NGR 基团组成的多肽的脱酰胺产物。
• TARGET ACTIVATED CELL/TISSUE TRANSLOCATION PEPTIDE FOR IMPERMEABLE COMPOUND STRATEGY, AND USES THEREOF
  申请人：Nano Intelligent Biomedical Engineering Corporation Co., Ltd.

  公开号：EP2399939A2

  公开（公告）日：2011-12-28

  The present invention relates to a target-activated cell/tissue-penetrating peptide for delivery of impermeable compounds (Target Activated Cell/tissue Translocation peptide for Impermeable Compound Strategy (TACTICS)), and the use thereof, and more particularly to a target-activated cell/tissue-penetrating peptide, which comprises (a) a protein transduction domain (PTD), (b) a masking domain and (c) a spacer having a cleavage site specific for a target cell/tissue enzyme and is provided with target selectivity so as to penetrate specifically into a target tissue, and to a conjugate of the peptide with a drug or drug-containing particles for imaging or therapeutic applications. Because the target-activated cell/tissue-penetrating peptide has target selectivity, the peptide-drug conjugate exhibits maximized imaging and therapeutic effects, and the non-specific distribution of the conjugate in vivo is inhibited, so that the side effects of the conjugate are minimized, the diagnostic effects of the conjugate are maximized, and the conjugate is useful for the treatment of disease.

  本发明涉及一种用于递送防渗化合物的靶向激活细胞/组织穿透肽（TACTICS）及其用途，特别是涉及一种靶向激活细胞/组织穿透肽、它包括(a)蛋白质转导结构域（PTD）、(b)屏蔽结构域和(c)具有靶细胞/组织酶特异性裂解位点的间隔物，并具有靶选择性，可特异性地穿透到靶组织中，还包括该多肽与药物或含药微粒的共轭物，用于成像或治疗应用。由于靶向激活的细胞/组织穿透肽具有靶向选择性，肽-药物共轭物显示出最大的成像和治疗效果，共轭物在体内的非特异性分布受到抑制，因此共轭物的副作用最小，共轭物的诊断效果最大，共轭物可用于治疗疾病。
• Vaccines based on targeting antigen to dcir expressed on antigen-presenting cells
  申请人：Baylor Research Institute

  公开号：EP2527363A1

  公开（公告）日：2012-11-28

  The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.

  本发明包括使用 DCIR 特异性抗体或其片段提高抗原呈递效率的组合物和方法，该抗体或其片段上附着抗原，形成抗体-抗原复合物，其中抗原由与抗体-抗原复合物接触的树突状细胞处理和呈递。
• Transferrin variants and conjugates
  申请人：Novozymes Biopharma DK A/S

  公开号：EP2604623A2

  公开（公告）日：2013-06-19

  Based on the three-dimensional structure of transferrin, the inventors have designed variant polypeptides (muteins) which have one or more Cysteine residues with a free thiol group (hereinafter referred to as "thiotransferrin"). The variant polypeptide may be conjugated through the sulphur atom of the Cysteine residue to a bioactive compound.

  根据转铁蛋白的三维结构，本发明者设计了变体多肽（静音蛋白），其中一个或多个半胱氨酸残基带有游离硫醇基团（以下简称 "硫代转铁蛋白"）。变体多肽可通过半胱氨酸残基的硫原子与生物活性化合物共轭。